

**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
TOP\$ Virtual Review
Via Videoconferencing
May 6, 2022
9:00 AM**

- I. Call to Order.....Ben Orlando
- II. Parliamentary Business Ben Orlando
 - A. Introduction of Members/Roll Call
 - B. Attendance/Additional Meetings
- III. P & T Committee Review Virtual Process.....Hind Douiki
- IV. Reports.....Sue Fontenot
 - A. PDL Reflecting Fall 2021 Recommendations
 - B. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – January 14, 2022
- V. New Business.....Hind Douiki
 - A. Explanation of TOP\$, Monographs and Cost Sheets
 - B. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony
 - 1. Acne Agents, Topical
 - 2. Analgesics, Narcotics Long
 - 3. Analgesics, Narcotics Short
 - 4. Androgenic Agents
 - 5. Angiotensin Modulator Combinations
 - 6. Angiotensin Modulators
 - 7. Antibiotics, GI
 - 8. Antibiotics, Inhaled
 - 9. Antibiotics, Topical
 - 10. Antibiotics, Vaginal
 - 11. Anticoagulants
 - 12. Antiemetic/Antivertigo Agents
 - 13. Antifungals, Oral
 - 14. Antifungals, Topical
 - 15. Antimigraine Agents, Other
 - 16. Antimigraine Agents, Triptans
 - 17. Antiparasitics, Topical
 - 18. Antivirals, Oral
 - 19. Antivirals, Topical
 - 20. Beta-Blockers
 - 21. Bladder Relaxant Preparations
 - 22. Bone Resorption Suppression and Related Agents
 - 23. BPH Treatments
 - 24. Calcium Channel Blockers

25. Cephalosporins and Related Antibiotics
26. Cystic Fibrosis, Oral
27. Fluoroquinolones, Oral
28. GI Motility, Chronic
29. Glucagon Agents
30. Growth Factors
31. Growth Hormone
32. H. Pylori Treatment
33. HAE Treatments
34. HIV/AIDS
35. Hypoglycemics, Alpha-Glucosidase Inhibitors
36. Hypoglycemics, Incretin Mimetics/Enhancers
37. Hypoglycemics, Insulin and Related Agents
38. Hypoglycemics, Meglitinides
39. Hypoglycemics, Metformins
40. Hypoglycemics, SGLT2
41. Hypoglycemics, Sulfonylureas
42. Hypoglycemics, TZD
43. Immunosuppressives, Oral
44. Lincosamides/Oxazolidinones/Streptogramins
45. Lipotropics, Other
46. Lipotropics, Statins
47. Macrolides/Ketolides
48. Multiple Sclerosis Agents
49. Nitrofurans Derivatives
50. Opiate Dependence Treatments
51. PAH Agents, Oral and Inhaled
52. Pancreatic Enzymes
53. Pediatric Vitamin Preparations
54. Phosphate Binders
55. Pituitary Suppressive Agents, LHRH
56. Platelet Aggregation Inhibitors
57. Pleuromutilins
58. Potassium Binders
59. Proton Pump Inhibitors
60. Sinus Node Inhibitors
61. Skeletal Muscle Relaxants
62. Tetracyclines
63. Ulcerative Colitis Agents
64. Uterine Disorder Treatments
65. Vasodilators, Coronary

C. Hepatitis C Agents

- VI. New & Other Single Drug Reviews.....Hind Douiki
66. Anticonvulsants – Eprontia[®] Solution (Oral)

67. Antipsychotics - Lybalvi[®] (Oral)
68. Antipsychotics – Invega Hafyera[®] (Intramusc)
69. Bile Salts - Livmarli[®] (Oral)
70. Immunomodulators, Atopic Dermatitis – Adbry[®] (Subcutaneous)
71. Immunomodulators, Atopic Dermatitis – Opzelura[®] (Topical)
72. Oncology, Oral – Hematologic - Scemblix[®] (Oral)
73. Oncology, Oral – Lung - Exkivity[®] (Oral)
74. Ophthalmics, Anti-Inflammatory/Immunomodulator – Tyrvaya[®] Spray (Nasal)
75. Ophthalmics, Glaucoma Agents – Vuity[®] (Ophthalmic)

VII. Fall Brand Over Generic Changes

76. Anticonvulsants—Felbamate tablet (Oral)
77. Antihypertensives, Sympatholytics—Clonidine (Transderm)
78. Antipsychotics—Asenapine AG, Generic (Sublingual)
79. Antipsychotics—Ziprasidone (Intramusc)
80. Enzyme Replacement, Gauchers Disease—Zavesca[®] (Oral)
81. Oncology, Oral—Renal Cell—Sunitinib (Oral)
82. Smoking Cessation—Varenicline Tartrate (Oral)

VIII. Other Business

IX. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

X. Next Meeting Date – Wednesday, October/November 2022

XI. Public Testimony